Pharmafile Logo

Multi-level Segmentation Solution

September 6, 2017 | Case study, Quantitative, Segmentation 

Our client has an established product for multiple indications. They wanted to create a HCP segmentation typing tool which could be implemented in-field to help classify physicians across two different therapeutic areas. There was rationale to suggest that because the two therapeutic areas are pathologically different, then two separate typing tools would be required. However, it was also argued that a one segment solution would be most suitable as physicians fundamentally have the same attitudes, irrespective of the disease they are treating. Additionally, our client would be able to implement a single segmentation tool into its core business much more efficiently than two separate tools. The challenge was to therefore decide whether a one tool or two tool solution would be most suitable.

Find out more: https://www.researchpartnership.com/news/2017/08/multi-level-segmentation-solution/

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Exploring MINT: Part 3 – Nigeria

In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.

Exploring MINT: Part 2 – Indonesia

In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...

Pegasus Wins ‘Consultancy of the Year’ at Communiqué Awards 2014

Pegasus, the UK’s leading independent health communications consultancy, picked up the much coveted ‘Consultancy of the Year’ award at last week’s Communiqué Awards 2014, fighting off stiff competition from the...

Free Thinking: Leveraging the ASEAN Market

If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to...

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

The Next Billion Patients

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

Huge Untapped Growth Potential of ASEAN

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

The power of observation in gathering patient insights

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.

Market Insights Can Deliver a Better Patient Experience

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding

Excellence in oncology: Developing an effective biomarker strategy

Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,...